Yazar "Erer, Kerim" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Is there a relationship between stem cell yield obtained from healthy donors and healthy donors' blood type?
    (Pergamon-Elsevier Science Ltd, 2025) Katircilar, Yavuz; Sahin, Abdulkadir; Aydin, Muruvvet Seda; Erer, Kerim; Erkurt, Mehmet Ali; Namdaroglu, Sinem; Yilmaz, Seda
    Background and objectives: Factors affecting adequate mobilization and apheresis are critical for a good yield of hematopoietic stem cells (HSCs) in the final product. A female donor, advanced age, smoking, high lactate dehydrogenase levels, high absolute lymphocyte count at baseline were found to be inversely correlated to the number of harvested CD34+ cells. However, the data on whether there is a correlation between blood types A, B, AB, O and the number of harvested CD34+ cells is insufficient. The aim of this study is to investigate the effect of blood types on the stem cell yield in healthy donors. Material and methods: A total of 807 healthy donors from 10 centers in T & uuml;rkiye were included in this retrospective study. Donors were subdivided into four groups as A, B, AB, O by their blood types. These four groups were compared in terms of age, sex, ECOG performance score, smoking status, and the amount of harvested CD34+ stem cells. Results: The median age of the 807 healthy donors included in the study was 35 years (11-70). 256 (31.7 %) donors were female and 551 (68.2 %) donors were male. There were 349 donors in type A blood group, 134 in type B blood group, 53 in type AB blood group and 271 donors in type O blood group. The median amount of CD34+ cells in the total apheresis product was 7.67 x 106 per kg in type O blood group, 7.52 x 106 per kg in type A blood group, 7.2 x 106 per kg in type B blood group, and 7.45 x 106 per kg in type AB blood group. There was no statistically significant difference among the groups (p:0.673). Smoking was lower in the type B blood group with 29.1 % compared to the other groups. However, there was no statistically significant difference in total amount of CD34+ stem cells in the type B blood group who smoked less (p = 0.949). Conclusion: In our study in which we have retrospectively analyzed the effect of donor blood types on the efficiency of HSCs harvested from peripheral blood in healthy donors, no correlation was found between the blood types and the mobilization and amount of harvested CD34+ cells.
  • Küçük Resim Yok
    Öğe
    What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?
    (Pergamon-Elsevier Science Ltd, 2025) Ulas, Turgay; Namdaroglu, Sinem; Hindilerden, Ipek Yonal; Erkurt, Mehmet Ali; Erer, Kerim; Yigenoglu, Tugce Nur; Tiryaki, Tarik Onur
    Objectives: In this study, we aimed to compare the engraftment days, graft versus host disease (GVHD) development, relapse and overall survival (OS) rates in patients using variable intensity conditioning regimens with two different post-transplant cyclophosphamide (PTCy) doses for hematological malignancies. Material and methods: We retrospectively analyzed 162 patients who have had PTCy at a dose of 25 mg/kg x 2 and 50 mg/kg x 2 between 2018 and 2024. Patients were divided in 2 groups; PTCy dose with 25 mg/kg x 2 (Group 1, n = 45) and PTCy dose with 50 mg/kg x 2 (Group 2, n = 117). The engraftment days, GVHD, relapse and OS rates were compared across groups. Results: All patients had myeloablative conditioning regimens and peripheral stem cell collected transplantation. 61.1 % of patients (n = 99) were alive at the end of the study (60 % (n = 27) in Group1 and 61.5 % (n = 72) in Group 2). In Group 1 the median follow-up was 6.9 months and in Group 2 this was 7 months; the median OS was 15.5 months in Group 1 and 49.5 months in Group 2 but this is not statistically significant (Log rank = 0.796). In Group 1, the engraftment times for platelets was 13 days, for neutrophils 17 days; in Group 2, for platelet this was 18 days; and for neutrophils 17 days; this was statistically significant for platelets but not for neutrophil engraftment (p: < 0.001 and p:0.839, respectively). Eighteen patients (40 %) in Group 1 and twenty-seven (23 %) patients in group 2 had acute GVHD (aGVHD). In Group 1 aGVHD rates were higher than Group 2 (p = 0.031). Seven patients (15.5 %) in Group 1 and 6 (5.12 %) patients in group 2 had chronic GVHD (cGVHD). In Group 1 cGVHD rates were also higher than Group 2 (p = 0.048). Twenty-five patients (55.6 %) in Group 1 and 19 patients (16.2 %) in Group 2 had relapsed disease (p < 0.001). Conclusion: Our study showed that there were no differences in survival across the groups. The platelet engraftment time was shorter for the PTCy 25 mg/kg x 2 doses compared to the post-transplantation 50 mg/kg x 2 doses. Both aGVHD and cGVHD rates were higher in 25 mg/kg x 2 dose treated patients. Relapses occurred more commonly with 25 mg/kg x 2 PTCy dose.